Seattle's Immune Design Corporation Files For $60 Million IPO
Published: Jun 27, 2014
Seattle-based biotechnology company Immune Design wants to raise $60 million in an initial public offering to take its immune-based therapies to fight off cancer and other chronic diseases to the next round of clinical trials.
Immune Design, a Seattle biotechnology company working on immune-based therapies to fight cancer, has filed documents with the Securities and Exchange Commission to go public.
For the SEC filing, please click here.
Help employers find you! Check out all the jobs and post your resume.